Indeed, administration of the abovementioned NPs resulted in antigen-specific CD8+ CTL responses, characterized by IFN-γ production and increase of pro-inflammatory cytokines in the tumor microenvironment (TME) (59). The gene discussed is CD8A; the disease is neoplasm.